Chronic activation of γ2 AMPK induces obesity and reduces β cell function
Despite significant advances in our understanding of the biology determining systemic energy homeostasis, the treatment of obesity remains a medical challenge. Activation of AMP-activated protein kinase (AMPK) has been proposed as an attractive strategy for the treatment of obesity and its complicat...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Cell Press
2016
|
| _version_ | 1797067306906419200 |
|---|---|
| author | Yavari, A Stocker, C Ghaffari, S Wargent, E Steeples, V Czibik, G Pinter, K Bellahcene, M Oliver, P Stockenhuber, A Nguyen, C Lazdam, M Kyriakou, T Parnis, J Sarma, D Katritsis, G Wortmann, D Harper, A Brown, L Peirson, S Redwood, C Watkins, H Ashrafian, H |
| author_facet | Yavari, A Stocker, C Ghaffari, S Wargent, E Steeples, V Czibik, G Pinter, K Bellahcene, M Oliver, P Stockenhuber, A Nguyen, C Lazdam, M Kyriakou, T Parnis, J Sarma, D Katritsis, G Wortmann, D Harper, A Brown, L Peirson, S Redwood, C Watkins, H Ashrafian, H |
| author_sort | Yavari, A |
| collection | OXFORD |
| description | Despite significant advances in our understanding of the biology determining systemic energy homeostasis, the treatment of obesity remains a medical challenge. Activation of AMP-activated protein kinase (AMPK) has been proposed as an attractive strategy for the treatment of obesity and its complications. AMPK is a conserved, ubiquitously expressed, heterotrimeric serine/threonine kinase whose short-term activation has multiple beneficial metabolic effects. Whether these translate into long-term benefits for obesity and its complications is unknown. Here, we observe that mice with chronic AMPK activation, resulting from mutation of the AMPK γ2 subunit, exhibit ghrelin signalling-dependent hyperphagia, obesity and impaired pancreatic islet insulin secretion. Humans bearing the homologous mutation manifest a congruent phenotype. Our studies highlight that longterm AMPK activation throughout all tissues can have adverse metabolic consequences, with implications for pharmacological strategies seeking to chronically activate AMPK systemically to treat metabolic disease. |
| first_indexed | 2024-03-06T21:54:23Z |
| format | Journal article |
| id | oxford-uuid:4c6a4682-da59-4812-89f8-36449b4fb3d5 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:54:23Z |
| publishDate | 2016 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:4c6a4682-da59-4812-89f8-36449b4fb3d52022-03-26T15:49:16ZChronic activation of γ2 AMPK induces obesity and reduces β cell functionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4c6a4682-da59-4812-89f8-36449b4fb3d5Symplectic Elements at OxfordCell Press2016Yavari, AStocker, CGhaffari, SWargent, ESteeples, VCzibik, GPinter, KBellahcene, MOliver, PStockenhuber, ANguyen, CLazdam, MKyriakou, TParnis, JSarma, DKatritsis, GWortmann, DHarper, ABrown, LPeirson, SRedwood, CWatkins, HAshrafian, HDespite significant advances in our understanding of the biology determining systemic energy homeostasis, the treatment of obesity remains a medical challenge. Activation of AMP-activated protein kinase (AMPK) has been proposed as an attractive strategy for the treatment of obesity and its complications. AMPK is a conserved, ubiquitously expressed, heterotrimeric serine/threonine kinase whose short-term activation has multiple beneficial metabolic effects. Whether these translate into long-term benefits for obesity and its complications is unknown. Here, we observe that mice with chronic AMPK activation, resulting from mutation of the AMPK γ2 subunit, exhibit ghrelin signalling-dependent hyperphagia, obesity and impaired pancreatic islet insulin secretion. Humans bearing the homologous mutation manifest a congruent phenotype. Our studies highlight that longterm AMPK activation throughout all tissues can have adverse metabolic consequences, with implications for pharmacological strategies seeking to chronically activate AMPK systemically to treat metabolic disease. |
| spellingShingle | Yavari, A Stocker, C Ghaffari, S Wargent, E Steeples, V Czibik, G Pinter, K Bellahcene, M Oliver, P Stockenhuber, A Nguyen, C Lazdam, M Kyriakou, T Parnis, J Sarma, D Katritsis, G Wortmann, D Harper, A Brown, L Peirson, S Redwood, C Watkins, H Ashrafian, H Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title | Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title_full | Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title_fullStr | Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title_full_unstemmed | Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title_short | Chronic activation of γ2 AMPK induces obesity and reduces β cell function |
| title_sort | chronic activation of γ2 ampk induces obesity and reduces β cell function |
| work_keys_str_mv | AT yavaria chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT stockerc chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT ghaffaris chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT wargente chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT steeplesv chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT czibikg chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT pinterk chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT bellahcenem chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT oliverp chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT stockenhubera chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT nguyenc chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT lazdamm chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT kyriakout chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT parnisj chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT sarmad chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT katritsisg chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT wortmannd chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT harpera chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT brownl chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT peirsons chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT redwoodc chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT watkinsh chronicactivationofg2ampkinducesobesityandreducesbcellfunction AT ashrafianh chronicactivationofg2ampkinducesobesityandreducesbcellfunction |